Swiss National Bank’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.54M | Buy |
320,000
+10,400
| +3% | +$143K | ﹤0.01% | 1386 |
|
|
2026
Q1 | $3.85M | Hold |
309,600
| – | – | ﹤0.01% | 1497 |
|
|
2025
Q4 | $3.9M | Buy |
309,600
+5,900
| +2% | +$67.5K | ﹤0.01% | 1494 |
|
|
2025
Q3 | $3.04M | Buy |
303,700
+4,300
| +1% | +$38.6K | ﹤0.01% | 1629 |
|
|
2025
Q2 | $2.42M | Buy |
299,400
+29,300
| +11% | +$221K | ﹤0.01% | 1686 |
|
|
2025
Q1 | $2.26M | Sell |
270,100
-3,900
| -1% | -$32.6K | ﹤0.01% | 1688 |
|
|
2024
Q4 | $2.17M | Buy |
274,000
+31,900
| +13% | +$268K | ﹤0.01% | 1806 |
|
|
2024
Q3 | $2.01M | Hold |
242,100
| – | – | ﹤0.01% | 1851 |
|
|
2024
Q2 | $1.54M | Hold |
242,100
| – | – | ﹤0.01% | 1945 |
|
|
2024
Q1 | $1.47M | Buy |
242,100
+29,400
| +14% | +$166K | ﹤0.01% | 2012 |
|
|
2023
Q4 | $1.29M | Buy |
+212,700
| New | +$947K | ﹤0.01% | 2102 |
|
|
2023
Q2 | – | Sell |
-212,500
| Closed | -$295K | – | 2607 |
|
|
2023
Q1 | $295K | Sell |
212,500
-25,100
| -11% | -$50K | ﹤0.01% | 2610 |
|
|
2022
Q4 | $473K | Buy |
237,600
+8,000
| +3% | +$17.9K | ﹤0.01% | 2582 |
|
|
2022
Q3 | $464K | Hold |
229,600
| – | – | ﹤0.01% | 2594 |
|
|
2022
Q2 | $730K | Hold |
229,600
| – | – | ﹤0.01% | 2506 |
|
|
2022
Q1 | $957K | Buy |
229,600
+18,100
| +9% | +$80.2K | ﹤0.01% | 2431 |
|
|
2021
Q4 | $1.01M | Hold |
211,500
| – | – | ﹤0.01% | 2474 |
|
|
2021
Q3 | $1.13M | Hold |
211,500
| – | – | ﹤0.01% | 2376 |
|
|
2021
Q2 | $1.08M | Sell |
211,500
-5,500
| -3% | -$31.3K | ﹤0.01% | 2444 |
|
|
2021
Q1 | $1.46M | Hold |
217,000
| – | – | ﹤0.01% | 2183 |
|
|
2020
Q4 | $992K | Hold |
217,000
| – | – | ﹤0.01% | 2289 |
|
|
2020
Q3 | $842K | Buy |
217,000
+22,500
| +12% | +$96.2K | ﹤0.01% | 2174 |
|
|
2020
Q2 | $926K | Sell |
194,500
-13,600
| -7% | -$56K | ﹤0.01% | 2148 |
|
|
2020
Q1 | $724K | Buy |
208,100
+11,800
| +6% | +$50K | ﹤0.01% | 1999 |
|
|
2019
Q4 | $946K | Buy |
196,300
+25,100
| +15% | +$87.3K | ﹤0.01% | 2170 |
|
|
2019
Q3 | $496K | Hold |
171,200
| – | – | ﹤0.01% | 2364 |
|
|
2019
Q2 | $1.23M | Buy |
171,200
+3,600
| +2% | +$36.8K | ﹤0.01% | 2002 |
|
|
2019
Q1 | $2.38M | Buy |
167,600
+96,500
| +136% | +$1.28M | ﹤0.01% | 1562 |
|
|
2018
Q4 | $962K | Sell |
71,100
-111,000
| -61% | -$2M | ﹤0.01% | 2035 |
|
|
2018
Q3 | $4.04M | Buy |
182,100
+59,200
| +48% | +$1.25M | ﹤0.01% | 1249 |
|
|
2018
Q2 | $2.02M | Buy |
+122,900
| New | +$2.16M | ﹤0.01% | 1713 |
|
Other funds holding AMRX
TGA
RCMNY
Swiss National Bank's AMRX Position: Q2 2026 in Review
Swiss National Bank increased its Amneal Pharmaceuticals (AMRX) stake by 3.4% in Q2 2026, buying an estimated $143K and bringing the position to 320,000 shares worth $5.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1386.
Swiss National Bank first reported a position in AMRX in Q2 2018 and has held it in 31 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- Swiss National Bank held 320,000 shares of Amneal Pharmaceuticals worth $5.54M as of Q2 2026.
- Swiss National Bank bought 10,400 Amneal Pharmaceuticals shares in Q2 2026, an estimated $143K.
- Amneal Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1386 holding.
- Swiss National Bank first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 31 quarters since.
- 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.